A comparative study of intraperitoneal perfusion of lobaplatin and cisplatin in the treatment of malignant ascites

Abstract

Objective To compare the efficacy and safety of intraperitoneal perfusion of lobaplatin and cisplatin in the treatment of malignant ascites, and summarize the reasonable treatment plan to improve the prognosis. Methods We chose 58 patients with malignant ascites in our hospital. All the patients were divided into two groups according to the infusion drug, and treated with lobaplatin 30 mg/m2 and cisplatin 60 mg/m2 respectively. Then we evaluated the curative effect, life quality score, and the toxicity of two groups. Results There were no statistically significant differences in the life quality score and short-term efficacy between two groups (P>0.05). The incidence of toxic reaction was 20.0% in lobaplatin group and 28.6% in cisplatin group, with statistically significant difference (P<0.05). Conclusions (1) Both lobaplatin and cisplatin infusion can control malignant ascites well, with equivalent overall curative effect; (2) from the point of view of drug safety, intraperitoneal infusion of loboplatin is more safe, with less toxic side effects. Key words: Lobaplatin; Cisplatin; Malignant ascites; Perfusion therapy; Curative effect